Matches in SemOpenAlex for { <https://semopenalex.org/work/W2290871005> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W2290871005 abstract "17134 Background: Chemotherapy prolongs survival of patients with advanced non-small cell lung cancer (NSCLC). Subanalysis of a phase III trial suggests better outcome of treatment with platinum and gemcytabine containing combinations in patients with adenocarcinoma. Also docetaxel is active in NSCLC. The aim of this phase II trial was to wvaluate the efficacy and tolerability of third generation doublet (GCB and DXL) in cheminaive patients with advanced adenocarcinoma of lung. Methods: Chemonaive patients with biopsy proven stage IIIB or IV adenocarcinoma of lung not suitable for curative radical treatment witk KPS 80–100 received 2 to 6 chemotherapy cycles (DXL 80 mg/m 2 day 1 plus GCB 1000 mg/m 2 day 1 and 8; every 21 days). Response rate and tolerability were the primary endpionts, while the overall survival and 1-year survival were secondary objectives. Results: Twenty eigth patients (15 women, 13 men) with median age 59,04 (range 40–74) were treated. Twenty three patients was analysed. Stage IV was found in 23 (95.8%) and stage IIIB in 1 (4.2%) patients. Partial response was achiwed in 9 (37,5%), stable disease in 12 (50%) and pregressive disease in 3 (12,5%) patients. Median time to progression was 8, 37 months (range: 1.5–14 months). Median overall survival was 12,87 months (range: 4–35 months). Eleven (11) patients received second-line therapy (6-RT, 11-CTH). All patients received 94 cycles of chemotherapy (range: 2, median 3,9). Total dose of docetaxel on each patients was fro 120 to 960 mg (median 556 mg). Total dose of gemcytabine on each patients was from 2100 mg to 21000 mg (median 10475 mg). Treatment toxicicy presents on the table . Conclusions: First line gemcytabine and docetaxel containing chemotherapy is effective palliative treatment for patients with advanced AC of the lung. Toxicity was within acceptable limits. [Table: see text] No significant financial relationships to disclose." @default.
- W2290871005 created "2016-06-24" @default.
- W2290871005 creator A5039423446 @default.
- W2290871005 creator A5044294458 @default.
- W2290871005 creator A5045400335 @default.
- W2290871005 creator A5058046400 @default.
- W2290871005 creator A5058280907 @default.
- W2290871005 creator A5073572288 @default.
- W2290871005 creator A5091600210 @default.
- W2290871005 date "2006-06-20" @default.
- W2290871005 modified "2023-10-14" @default.
- W2290871005 title "Efficacy and tolerability of gemcytabine plus docetaxel in patients with locally advanced or metastatic adenocarcinoma of the lung" @default.
- W2290871005 doi "https://doi.org/10.1200/jco.2006.24.18_suppl.17134" @default.
- W2290871005 hasPublicationYear "2006" @default.
- W2290871005 type Work @default.
- W2290871005 sameAs 2290871005 @default.
- W2290871005 citedByCount "0" @default.
- W2290871005 crossrefType "journal-article" @default.
- W2290871005 hasAuthorship W2290871005A5039423446 @default.
- W2290871005 hasAuthorship W2290871005A5044294458 @default.
- W2290871005 hasAuthorship W2290871005A5045400335 @default.
- W2290871005 hasAuthorship W2290871005A5058046400 @default.
- W2290871005 hasAuthorship W2290871005A5058280907 @default.
- W2290871005 hasAuthorship W2290871005A5073572288 @default.
- W2290871005 hasAuthorship W2290871005A5091600210 @default.
- W2290871005 hasConcept C121608353 @default.
- W2290871005 hasConcept C126322002 @default.
- W2290871005 hasConcept C143998085 @default.
- W2290871005 hasConcept C197934379 @default.
- W2290871005 hasConcept C2776694085 @default.
- W2290871005 hasConcept C2777714996 @default.
- W2290871005 hasConcept C2778375690 @default.
- W2290871005 hasConcept C2781182431 @default.
- W2290871005 hasConcept C2781190966 @default.
- W2290871005 hasConcept C2910665457 @default.
- W2290871005 hasConcept C71924100 @default.
- W2290871005 hasConceptScore W2290871005C121608353 @default.
- W2290871005 hasConceptScore W2290871005C126322002 @default.
- W2290871005 hasConceptScore W2290871005C143998085 @default.
- W2290871005 hasConceptScore W2290871005C197934379 @default.
- W2290871005 hasConceptScore W2290871005C2776694085 @default.
- W2290871005 hasConceptScore W2290871005C2777714996 @default.
- W2290871005 hasConceptScore W2290871005C2778375690 @default.
- W2290871005 hasConceptScore W2290871005C2781182431 @default.
- W2290871005 hasConceptScore W2290871005C2781190966 @default.
- W2290871005 hasConceptScore W2290871005C2910665457 @default.
- W2290871005 hasConceptScore W2290871005C71924100 @default.
- W2290871005 hasLocation W22908710051 @default.
- W2290871005 hasOpenAccess W2290871005 @default.
- W2290871005 hasPrimaryLocation W22908710051 @default.
- W2290871005 hasRelatedWork W1974503127 @default.
- W2290871005 hasRelatedWork W2109334940 @default.
- W2290871005 hasRelatedWork W2130723476 @default.
- W2290871005 hasRelatedWork W2315587357 @default.
- W2290871005 hasRelatedWork W2347520915 @default.
- W2290871005 hasRelatedWork W2383259583 @default.
- W2290871005 hasRelatedWork W3029039913 @default.
- W2290871005 hasRelatedWork W3032029751 @default.
- W2290871005 hasRelatedWork W3155373832 @default.
- W2290871005 hasRelatedWork W4231274199 @default.
- W2290871005 isParatext "false" @default.
- W2290871005 isRetracted "false" @default.
- W2290871005 magId "2290871005" @default.
- W2290871005 workType "article" @default.